Godavari Drugs
Godavari Drugs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Godavari Drugs
Start SIPGodavari Drugs Investment Rating
-
Master Rating:
-
Godavari Drugs has an operating revenue of Rs. 166.54 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 4% needs improvement, ROE of 17% is exceptional. The company has a reasonable debt to equity of 40%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 6% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 23% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at D which indicates heavy supply, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 39 | 41 | 43 | 44 |
| Operating Expenses Qtr Cr | 37 | 38 | 40 | 42 |
| Operating Profit Qtr Cr | 2 | 3 | 2 | 3 |
| Depreciation Qtr Cr | 1 | 0 | 0 | 0 |
| Interest Qtr Cr | 1 | 1 | 1 | 1 |
| Tax Qtr Cr | 0 | 0 | 0 | 1 |
| Net Profit Qtr Cr | 1 | 1 | 1 | 1 |
Godavari Drugs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 3
- Bearish Moving Average
- ___
- 13
- 20 Day
- 79.36
- 50 Day
- 80.7
- 100 Day
- 79.16
- 200 Day
- 75.16
- 20 Day
- 78.72
- 50 Day
- 82.72
- 100 Day
- 79.15
- 200 Day
- 73.04
Godavari Drugs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 80.12 |
| Second Resistance | 81.06 |
| Third Resistance | 82.12 |
| RSI | 44.49 |
| MFI | 54.56 |
| MACD Single Line | -1.17 |
| MACD | -0.93 |
| Support | |
|---|---|
| First Resistance | 78.12 |
| Second Resistance | 77.06 |
| Third Resistance | 76.12 |
Godavari Drugs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 3,906 | 261,390 | 66.92 |
| Week | 5,390 | 389,129 | 72.2 |
| 1 Month | 5,427 | 379,571 | 69.94 |
| 6 Month | 25,635 | 1,570,160 | 61.25 |
Godavari Drugs Result Highlights
Godavari Drugs Synopsis
BSE-Medical-Generic Drugs
Godavari Drugs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 161.11 Cr. and Equity Capital is Rs. 7.53 Cr. for the Year ended 31/03/2022. Godavari Drugs Ltd. is a Public Limited Listed company incorporated on 02/12/1987 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24230TG1987PLC008016 and registration number is 008016.| Market Cap | 59 |
| Sales | 167 |
| Shares in Float | 0.35 |
| No of funds | 4 |
| Yield |
| Book Value | 1.98 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | 40 |
| Alpha | 0.14 |
| Beta | 0.36 |
Godavari Drugs
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 53.12% | 56.92% | 56.92% | |
| Financial Institutions/ Banks | 0.5% | 0.5% | 0.5% | |
| Individual Investors | 39.26% | 35.9% | 35.87% | |
| Others | 7.12% | 6.68% | 6.71% |
Godavari Drugs Management
| Name | Designation |
|---|---|
| Mr. Ghanshyam Jaju | Chairman |
| Mr. Mukund Kakani | Managing Director |
| Mr. Mohit Jaju | Executive Director |
| Mr. Kirti Kumar Jain | CFO & Wholetime Director |
| Mr. Dilip Keshavlal Patel | Non Exe. & Ind. Director |
| Mr. Syed Anis Hussain | Non Exe. & Ind. Director |
| Mr. Ramesh Babu Telugu | Non Exe. & Ind. Director |
| Mrs. Vimala Madon | Non Exe. & Ind. Director |
Godavari Drugs Forecast
Price Estimates
Godavari Drugs FAQs
What is Share Price of Godavari Drugs ?
Godavari Drugs share price is ₹77 As on 30 March, 2023 | 17:02
What is the Market Cap of Godavari Drugs ?
The Market Cap of Godavari Drugs is ₹58.4 Cr As on 30 March, 2023 | 17:02
What is the P/E ratio of Godavari Drugs ?
The P/E ratio of Godavari Drugs is 15.7 As on 30 March, 2023 | 17:02
What is the PB ratio of Godavari Drugs ?
The PB ratio of Godavari Drugs is 2 As on 30 March, 2023 | 17:02